These data thus also suggest that the Wnt/PKC signaling pathway may be a novel target for developing a therapeutic intervention to target lung CSCs and reverse the cisplatin-resistance in lung cancer cells [17, 18, 21, 23, 25, 46–48]. Here, PRRT2 is linked to lung carcinoma.